Photodynamic therapy using aminolevulinic acid (ALA)

Ruediger Bachor; Ella Dumbravia Reich; Kurt Miller; Richard E. Hautmann

doi:10.1117/12.168677

1 March 1994 Photodynamic therapy using aminolevulinic acid (ALA)

Ruediger Bachor, Ella Dumbravia Reich, Kurt Miller, Richard E. Hautmann

Proceedings Volume 2078, Photodynamic Therapy of Cancer; (1994) https://doi.org/10.1117/12.168677
Event: Europto Biomedical Optics '93, 1993, Budapest, Hungary

Abstract

Photodynamic therapy (PDT) is a treatment modality for a variety of cancers. Since no ideal photosensitizer is available yet, new photosensitizers are being sought. A new concept of PDT is the use of endogenous photosensitizers. ALA is a metabolite in heme synthesis. It is a precursor of protoporphyrin IX, a potent photosensitizer. After administration of ALA it is transformed by the cells to protoporphyrin IX. The goal of our study was to examine dark toxicity of ALA and its phototoxic potential in two different human cell lines.

Citation Download Citation

Ruediger Bachor, Ella Dumbravia Reich, Kurt Miller, and Richard E. Hautmann "Photodynamic therapy using aminolevulinic acid (ALA)", Proc. SPIE 2078, Photodynamic Therapy of Cancer, (1 March 1994); https://doi.org/10.1117/12.168677

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available